Clinical results for a new Russian reagent kit based on the polymerase chain reaction for qualitative and quantitative in vitro determination of tuberculosis DNA
- 作者: Mikulovich Y.L.1, Zaytseva A.I.1, Lazebnyi S.V.2, Plekhanova M.A.2, Smerdin S.V.2, Shipulin G.A.1
-
隶属关系:
- Centre for Strategic Planning and Management of Biomedical Health Risks
- Moscow regional clinical antitubercular clinic
- 期: 卷 69, 编号 9 (2024)
- 页面: 186-197
- 栏目: Original Study Articles
- ##submission.datePublished##: 10.02.2025
- URL: https://kld-journal.fedlab.ru/0869-2084/article/view/636624
- DOI: https://doi.org/10.17816/cld636624
- ID: 636624
如何引用文章
详细
BACKGROUND: The global fight against tuberculosis (TB) continues. The timely prescription of anti-TB therapy requires the rapid and effective identification of the causative agent, the Mycobacterium tuberculosis complex. Molecular genetic testing is used to detect the pathogen’s DNA and to provide results on the day the biological material is submitted to a laboratory. The Center for Strategic Planning and Management of Biomedical Health Risks has developed an AmpliTest® MBT reagent kit for the qualitative and quantitative determination of M. tuberculosis complex DNA in samples of human biological material and bacterial cultures using polymerase chain reaction.
AIM: The aim of the study was to evaluate the efficacy of the new AmpliTest® MBT reagent kit compared to a similarly designed kit approved in Russia as an in vitro diagnostic medical device, based on pre-approval clinical studies.
MATERIALS AND METHODS: A total of 575 samples were evaluated, including 475 biological samples obtained from patients with pulmonary and extrapulmonary tuberculosis: sputum, n =115; bronchoalveolar lavage, n =109; biopsy (surgical material), n =145; urine, n =106; and 100 bacterial culture samples. All samples, except cultures, were processed with NALC-NaOH reagents to obtain precipitates, each of which was divided into four equal parts and analyzed using three versions of the AmpliTest® MBT kit and the reference AmpliTub-RV kit (Syntol LLC). Amplification was performed using CFX96, DTprime, Applied Biosystems QuantStudio 5, Rotor-Gene Q manually or with software to automatically record results. The efficacy parameters of the AmpliTest® MBT kit were calculated, i.e. positive and negative concordance of results (with 95% confidence interval). Linear correlation coefficient (R2) was determined for quantitative results.
RESULTS: There was complete concordance between the results of the qualitative determination of M. tuberculosis complex DNA in the samples tested using the new kit and the reference kit. The efficacy rates of the new AmpliTest® MBT kit were 100% for all samples. The linear correlation coefficients (R2) of the quantitative determinations of M. tuberculosis complex DNA were greater than 0.9.
CONCLUSION: Clinical studies of the new AmpliTest® MBT reagent kit demonstrated its high efficiency in the qualitative and quantitative determination of M. tuberculosis complex DNA in samples of human biological material and bacterial cultures compared to the reference kit.
全文:

作者简介
Yuliya Mikulovich
Centre for Strategic Planning and Management of Biomedical Health Risks
编辑信件的主要联系方式.
Email: YuMikulovich@cspfmba.ru
ORCID iD: 0009-0006-3662-7528
SPIN 代码: 8676-9256
Anastasiya Zaytseva
Centre for Strategic Planning and Management of Biomedical Health Risks
Email: AZaytseva@cspfmba.ru
ORCID iD: 0009-0007-9297-0256
俄罗斯联邦, 1 bldg., 10 Pogodinskaya street, 119121 Moscow
Sergei Lazebnyi
Moscow regional clinical antitubercular clinic
Email: nelazebnyi@mail.ru
ORCID iD: 0000-0002-8667-3614
俄罗斯联邦, Mytishchi
Maria Plekhanova
Moscow regional clinical antitubercular clinic
Email: dina-plus@mail.ru
ORCID iD: 0000-0003-1687-7598
SPIN 代码: 3595-8608
Sergei Smerdin
Moscow regional clinical antitubercular clinic
Email: mz_mokptd@mosreg.ru
ORCID iD: 0000-0002-2602-214X
SPIN 代码: 7649-0300
German Shipulin
Centre for Strategic Planning and Management of Biomedical Health Risks
Email: Shipulin@cspfmba.ru
ORCID iD: 0000-0002-3668-6601
SPIN 代码: 1908-9098
参考
- Nechaeva OB. TB situation in Russia. Tuberculosis and Lung Diseases. 2018;96(8):15–24. (In Russ.) doi: 10.21292/2075-1230-2018-96-8-15-24
- Global tuberculosis report 2021. Geneva: World Health Organization; 2021. Available from: https://iris.who.int/bitstream/handle/10665/346387/9789240037021-eng.pdf?sequence=1
- Global tuberculosis report 2023. Geneva: World Health Organization; 2023. Available from: https://iris.who.int/bitstream/handle/10665/373828/9789240083851-eng.pdf?sequence=1
- Order of the Ministry of Health of Russian Federation № 109 of 21 March 2003 “On improving anti-tuberculosis measures in the Russian Federation (as amended on June 5, 2017)”. Available from: https://docs.cntd.ru/document/901868614?section=text (In Russ.)
- Clinical recommendations. “Tuberculosis in adults”. 2024. Available from: https://cr.minzdrav.gov.ru/schema/16_3 (In Russ.)
- Оgarkov ОB, Medvedeva TV. Diagnosis of tuberculosis: clinical and epidemiological significance of the modern laboratory methods. Sibirskii meditsinskii zhurnal. 2004;42(1):5–9. (In Russ.) EDN: OTPFCJ
- Kozulitsyna TI. Microbiological research. In guide for doctors: Tuberkulez organov dykhaniya. Мoscow, 1981. P. 136–149. (In Russ.)
- Clopper C, Pearson E. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404–413. doi: 10.2307/2331986
- Van Embden J, Cave D, Crawford J, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol. 1993;31(2):406–409. doi: 10.1128/jcm.31.2.406-409.1993
- Van Soolingen D, de Haas PE, Hermans PW, et al. Comparison of various repetitive DNA elements as genetic markers for strain differentiation and epidemiology of Mycobacterium tuberculosis. J Clin Microbiol. 1993;31(8):1987–1995. doi: 10.1128/jcm.31.8.1987-1995.1993
- Mazurek GH, Cave MD, Eisenach KD, et al. Chromosomal DNA fingerprint patterns produced with IS6110 as strain-specific markers for epidemiologic study of tuberculosis. J Clin Microbiol. 1991;29(9):2030–2033. doi: 10.1128/jcm.29.9.2030-2033.1991
- Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med. 1994;330(24):1703–1709. doi: 10.1056/NEJM199406163302402
- Das S, Paramasivan CN, Lowrie DB, Prabhakar R, Narayanan PR. IS6110 restriction fragment length polymorphism typing of clinical isolates of Mycobacterium tuberculosis from patients with pulmonary tuberculosis in Madras, south India. Tuber Lung Dis. 1995;76(6):550–554. doi: 10.1016/0962-8479(95)90533-2
- Das S, Chan SL, Allen BW, Mitchison DA, Lowrie DB. Application of DNA fingerprinting with IS986 to sequential mycobacterial isolates obtained from pulmonary tuberculosis patients in Hong Kong before, during and after short-course chemotherapy. Tuber Lung Dis. 1993;74(1):47–51. doi: 10.1016/0962-8479(93)90068-9
- Goguet de la Salmoniere YO, Li HM, Torrea G, et al. Evaluation of spoligotyping in a study of the transmission of Mycobacterium tuberculosis. J Clin Microbiol. 1997;35(9):2210–2214. doi: 10.1128/jcm.35.9.2210-2214.1997
- Kremer K, van Soolingen D, Frothingham R, et al. Comparison of methods based on different molecular epidemiological markers for typing of Mycobacterium tuberculosis complex strains: interlaboratory study of discriminatory power and reproducibility. J Clin Microbiol. 1999;37(8):2607–2618. doi: 10.1128/JCM.37.8.2607-2618.1999
- Soini H, Pan X, Teeter L, Musser JM, Graviss EA. Transmission dynamics and molecular characterization of Mycobacterium tuberculosis isolates with low copy numbers of IS6110. J Clin Microbiol. 2001;39(1):217–221. doi: 10.1128/JCM.39.1.217-221.2001
- Lok KH, Benjamin WH Jr, Kimerling ME, et al. Molecular differentiation of Mycobacterium tuberculosis strains without IS6110 insertions. Emerg Infect Dis. 2002;8(11):1310–1313. doi: 10.3201/eid0811.020291
- Van Soolingen D, Hermans PW, de Haas PE, van Embden JD. Insertion element IS1081-associated restriction fragment length polymorphisms in Mycobacterium tuberculosis complex species: a reliable tool for recognizing Mycobacterium bovis BCG. J Clin Microbiol. 1992;30(7):1772–1777. doi: 10.1128/jcm.30.7.1772-1777.1992
- Chakravorty S, Simmons AM, Rowneki M, et al. The new Xpert MTB/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampin in an assay suitable for point-of-care testing. mBio. 2017;8(4):e00812–00817. doi: 10.1128/mBio.00812-17
- Yamaguchi R, Matsuo K, Yamazaki A, et al. Cloning and characterization of the gene for immunogenic protein MPB64 of Mycobacterium bovis BCG. Infect Immun. 1989;57(1):283–288. doi: 10.1128/iai.57.1.283-288.1989
- Armstrong DT, Pretty L, D'Agostino K, et al. Diagnostic Accuracy of the Abbott SD Bioline MPT64 antigen test for identification of MTB Complex in a U.S. Clinical Mycobacteriology Laboratory. Heliyon. 2024;10(9):e30501. doi: 10.1016/j.heliyon.2024.e30501
- Cormican MG, Barry T, Gannon F, Flynn J. Use of polymerase chain reaction for early identification of Mycobacterium tuberculosis in positive cultures. J Clin Pathol. 1992;45(7):601–604. doi: 10.1136/jcp.45.7.601
- Chaudhari KV, Toi PC, Joseph NM. Evaluation of real time polymerase chain reaction targeting mpb64 gene for diagnosis of extrapulmonary tuberculosis. Indian J Tuberc. 2021;68(2):242–248. doi: 10.1016/j.ijtb.2020.09.009
补充文件
